• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Work with us

DNDi Integrity Line

Home > Work with us

DNDi Integrity Line

  • Working at DNDi
  • Diversity, equity & inclusion
  • Code of Conduct
  • Integrity Line

DNDi’s Integrity Line is an online third-party platform that can be used for the anonymous reporting of misconduct by DNDi staff or anyone outside the organization in connection with DNDi activities.

The DNDi Integrity Line can be accessed directly here.

Operated by independent service provider EQS, the digital DNDi Integrity Line is available 24 hours a day, seven days a week, in eight languages. It offers a safe channel for staff, patients, partners, suppliers, and other stakeholders to report allegations of misconduct or to ask questions regarding ethics and standards of behaviour in connection with DNDi staff, partners, or projects. Those using the Integrity Line can choose to report anonymously, as EQS guarantees the anonymity of the complainant, through its secure servers.

A report received by the EQS server is sent to case managers at DNDi, who respond to the report and, if necessary, launch an investigation. The person who has filed the report will receive a response within 10 working days, and may communicate with the case manager via a secure, individual, password-protected message inbox on the EQS server. DNDi’s case managers’ titles are made available on the website. The complainant also has the choice to report allegations via Senior Manager, Compliance, Risk & Internal Control or a DNDi Ombudsperson (reporting to the Board), if they feel a case manager or their close entourage is conflicted.

The DNDi Integrity Line is one of the reporting channels supporting the whistleblowing process in DNDi’s Code of Conduct, DNDi’s Guidelines for the Prevention of Sexual Misconduct, and other DNDi policies and guidelines that require a mechanism for receiving complaints. Other reporting options include contacting any DNDi employee, director, or Board member, or contacting one of DNDi’s two Ombudspersons, described below.

The Integrity Line is not an emergency service and should not be used to report events presenting an immediate threat to safety or property. If you require emergency assistance, please contact your local authorities.

If you have questions regarding the DNDi Integrity Line, you can contact the DNDi Human Resources Director, Anderson Leal, at aleal@dndi.org or the Senior Manager, Compliance, Risk & Internal Control, Robert Grembowitz, at rgrembowitz@dndi.org.

Our policies

We strive to hold ourselves to the highest standards of accountability, transparency, ethics, and best practice in all we do.

read more

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License